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AntidepressantAbstract In the present study, a series of new substituted 5-(1H-Indol-3-yl)-3-(phenyl)-4,5-dihyd-
ropyrazoline derivatives (2a–m) have been synthesized with good yield by microwave assisted syn-
thesis. The compounds synthesized were screened for antidepressant and anticonvulsant
potentialities in mice by a forced swim test and subcutaneous pentylenetetrazole (scPTZ) test,
respectively. Neuro-toxicities were determined by rotarod test in albino mice. The structures of
all new compounds were conﬁrmed by IR, 1H NMR, mass spectral data, and microanalyses. The
results revealed that compounds 2b, 2e and 2k were found to be potent antidepressant molecules
of the series, at 20 mg/kg dose level when compared with the reference drugs imipramine and ﬂu-
oxetine. Whereas, compounds 2c and 2d were found to be potent anticonvulsant molecules of this
series, when compared with the reference drug diazepam. None of the synthesized compounds
showed neurotoxicity.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The discovery of new effective drugs for the treatment of
depression still remains a top priority as it affects approxi-
mately 21% of the world population. The World Health Orga-
nization (WHO) forecasts that; it will be the second leading
cause of death by the year 2020 owing to complications arising
from stress and the cardiovascular system (Lee et al., 2005).
Depression is a chronic, recurring and potentially life-threaten-
ing serious illness characterized by persistent feelings of sad-
ness, hopelessness, pessimism, guilt, loss of interest in
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levels of brain monoamines like norepinephrine, serotonin
and dopamine are considered responsible for depression. Re-
cent antidepressant agent increases the synaptic concentration
of either two (5-HT and NE) or all three (5-HT, NE and dopa-
mine (DA) neurotransmitters (Henn et al., 2004). Convulsions
or epilepsy is a chronic neurological disorder characterized by
the periodic and unpredictable occurrence of seizures that af-
fects the people of all ages with the incidence of 3% in the pop-
ulation (Gliman et al. 2001; Ibrahim et al., 2008). At present,
available antiepileptic drugs (AEDs) provide ample seizure
controls in many patients, still about 28–30% of patients are
estimated to be poorly treated (Yogeeswari et al., 2005). These
drugs have proven to be effective in reducing convulsions as
well as depression, at the same time their therapeutic efﬁcacy
is conquered by some undesirable side effects (Bialer et al.,
2004; Lerer and Macciardi, 2002). These observations of exist-
ing drugs, along with the sharp rise of depressive and convul-
sion cases in today’s scenario, prompted research in the ﬁeld of
antidepressant and anticonvulsant as a major thrust area.
Microwave heating, in recent time has taken an indubitable
place in organic synthesis as a very effective and ecofriendly
(Green) method of activation of reaction (Loupy et al., 1998;
Varma, 1999). The solvent-free microwave assisted reactions
have gained popularity as they provide potentialities to work
with open vessels and enhanced possibility of up-scaling the
reactions on a preparative scale (Paul et al., 2002; Dandia
et al., 2003; Deshayes et al. 1999).
Antidepressants and anticonvulsants are amongst the most
widely utilized drugs for the treatment of CNS disorders (Aziz
et al., 2009). Indole, the most useful heterocyclic nucleus has
gained prominence in medicinal chemistry due to its diverse
biological activities (Panda and Chaudhari, 2008, Biradar
et al., 2010, Renukadevi and Biradar, 1999, Bajaj et al.,
2003). Several studies have demonstrated the antidepressant
potential of indole derivatives (Sing and Gautam, 1977, Patil
and Bari, 2012, Ergenec et al., 1998; Varvaresou et al.,
1998). Similarly numerous indole derivatives are reported to
exhibit potent anticonvulsant activity (Singh et al., 1992, Popp,
1984, Sharma et al., 2010).
The 2-pyrazolines can be considered as a cyclic hydrazine
moiety and are considered as an important heterocyclic scaf-
fold for the development of potential antidepressant and anti-
convulsant agents. Pyrazoline derivatives were achieved via
treatment of chalcones (a,b-unsaturated ketones) with hydra-
zine derivatives (Parmar et al., 1974; Prasad et al., 2005). Pyr-
azoline nucleus has been reported to possess various
pharmacological activities (Joshi et al., 2010; Jeong et al.
2004; Acharya et al., 2010). So far, various substituted pyraz-
oline derivatives have been synthesized and investigated for
their antidepressant (Prasad et al., 2005; Gok et al., 2010; Pal-
aska et al., 2001) and anticonvulsant activities (Parmar et al.,
1974; Ozdemir et al., 2008; Aziz et al., 2009) and found high
activity. Prasad et al. and Parmar et al., had reported the syn-
thesis and antidepressant and anticonvulsant activity of 1,3,5
triphenyl 2-pyrazoline derivatives. Promising antidepressant
or anticonvulsant activity of some pyrazoline derivatives
prompted us to investigate them further. However, a pyrazo-
line ring has not appeared to be linked with indole so far. It
was hypothesized that the combination of both chemical sys-
tems in one compound with a cyclic hydrazine moiety, which
is prerequisite for antidepressant and anticonvulsant activity,may prove to be a breakthrough for the development of the
lead molecule for future antidepressant and anticonvulsant re-
search. These ﬁndings motivated us to link various heterocyclic
moieties to synthesize a new series of pyrazoline derivatives by
combining the indole moiety at the 5th position in order to
evaluate the effect of this substitution on antidepressant and
anticonvulsant activity. Based on the above mentioned facts,
and in continuation with our research on new heterocyclic
scaffold as an antidepressant (Patil and Bari, 2012), in the pro-
posed study we aim to investigate whether indolyl pyrazoline
derivatives show antidepressant and anticonvulsant activity
using the forced swimming and scPTZ test, respectively.
2. Methods and materials
2.1. Chemistry
All solvents and chemicals used in the synthesis were procured
from commercial suppliers and puriﬁed when necessary. All
microwave assisted reactions were performed using a scientiﬁc
microwave oven (Catalyst electromagnetic System) with a
power of 800 W specially designed for organic synthesis. The
completion of the reaction was monitored by thin layer chro-
matography performed on Merck precoated silica gel F254
plates. Silica gel (60–120 mesh size, Merck) was used for col-
umn chromatography. Melting points were recorded on an
Elico Melting Point Apparatus using open capillary tube and
were uncorrected. All NMR spectra were recorded on a Bruker
Advance III, 400 MHz spectrometer with CDCl3/DMSO as
solvent using tetramethyl silane (TMS) as internal reference
standard, chemical shifts are reported in ppm (d). The IR spec-
trum of synthesized compounds was recorded on a Schimadzu
IR 48 Spectrophotometer with DRS technology. Elemental
analyses were performed on a Vario-EL III CHNOS elemental
analyzer. Mass spectra were recorded on a 410 Prostar Binary
LC with 500 MS IT PDA detectors with direct infusion mass
with ESI and APCI Negative and Positive mode ionization.
2.2. General procedure for the synthesis of indolyl pyrazoline
derivatives (2a–m) using microwave
To a slurry of 1-(substituted 1H-indol-3-yl)-3-(substituted aryl)-
prop-1-en-3-ones (1 mmol) and phenyl hydrazine hydrochloride
(2 mmol) in 20 ml EtOH was added basic alumina (20 g) in a
100 ml beaker and mixed thoroughly. The reaction mixture
was air dried and subjected to microwave irradiation for speci-
ﬁed time at 455 W with 30 s pulse and cooled in between. The
reaction progress was monitored by TLC. After completion of
reaction as indicated by TLC, the reaction mixture was cooled
to room temperature and extracted into an organic solvent.
The in-organics were ﬁltered off. On standing the ﬁltrate affor-
ded crystals of desired pyrazolines (2a–m), which were puriﬁed
by column chromatography (Chloroform/Acetone 16:1 as elu-
ant). The structures of the isolated compounds were character-
ized by spectral methods and microanalyses. Melting point of
compounds 2a, 2b, 2c, 2e, 2g, 2k and 2m was conﬁrmed as re-
ported in the literature (Tsukerman et al., 1969).
2.2.1. 5-(1H-Indol-3-yl)-3-(phenyl)-4,5-dihydropyrazoline (2a)
Yield: 85.46%, reaction time: 12 min; m.p.: 178–180 C; IR
(KBr): cm1 3423 (N–H), 1614 (C‚C), 1597 (C‚N); 1H
590 P.O. Patil, S.B. BariNMR (400 MHz CDCl3, ppm): 5.61–5.64 (dd, 1H5c), 3.31–
3.36 (dd, 1H4a), 3.84–3.90 (dd, 1H4b), 6.79–6.82 (dd, 2H,
NArH), 7.15–7.26 (m, 2H, NArH), 7.34 (m, 1H, NArH),
7.34–7.52 (m, 4H, C3ArH), 7.68 (d, 1H, C3ArH), 7.25 (m,
1H, C5ArH), 7.78–7.82 (m, 1H, C5ArH), 7.06 (d, 1H,
C5ArH), 6.59 (s, 1H, C5ArH), 7.68 (d, 1H C5ArH), 7.96 (s,
1H, NH). 13C NMR (100 MHz CDCl3, ppm): 41.8, 57.9,
111.4, 113.6, 116.7, 118.9, 119.2, 119.9, 121.8, 112.5, 124.9,
126.9, 128.7, 128.8, 131.5, 134.2, 136.8, 145.0, 146.4. MS: m/
z 337.1 (M+), 338.1(M+1). Anal. Calcd. for C23H19N3: C,
81.87; H, 5.68; N, 12.45. Found: C, 81.85; H, 5.69; N, 12.46%.
2.2.2. 5-(1H-Indol-3-yl)-3-(4-methylphenyl)-4,5-
dihydropyrazoline (2b)
Yield: 84.52%; reaction time: 10 min; m.p.: 175–177 C; IR
(KBr): cm1 3414 (N–H), 1597 (C‚C), 1554 (C‚N); 1H
NMR (400 MHz CDCl3, ppm) 2.42 (s, 3H, CH3), 5.57–5.61
(dd, 1H5c), 3.29–3.34 (dd, 1H4a), 3.82–3.87 (dd, 1H4b), 6.79–
6.82 (t, 1H, NArH), 7.15–7.23 (m, 4H, NArH), 7.24–7.29 (m,
4H, C3ArH), 7.35–7.37 (d, 1H, C5ArH), 7.48–7.51 (t, 1H,
C5ArH), 7.67–7.69 (t, 1H, C5ArH), 7.04 (s, 1H, C5ArH),
7.80–7.87 (m, 1H, C5ArH), 7.96 (s, 1H, NH).
13C NMR
(100 MHz CDCl3, ppm): 21.4, 42.2, 57.7, 111.5, 113.6, 117.0,
118.9, 119.0, 119.1, 121.9, 112.4, 125.1, 125.8, 128.8, 129.3,
129.4, 129.5, 130.3, 136.9, 138.7, 145.6, 147.9. MS: m/z 351.2
(M+), 352.2(M+1). Anal. Calcd. for C24H21N3: C, 82.02; H,
6.02; N,11.96. Found: C, 82.05; H, 6.05; N, 11.93%.
2.2.3. 5-(1H-Indol-3-yl)-3-(4-chlorophenyl)-4,5-
dihydropyrazoline (2c)
Yield: 88.26%, reaction time: 15 min; m.p.: 160–161 C; IR
(KBr): cm1 3410 (N–H), 1595 (C‚C), 1504 (C‚N); 1H
NMR (400 MHz CDCl3, ppm) 5.61–5.65 (dd, 1H5c), 3.27–
3.32 (dd, 1H4a), 3.79–3.85 (dd, 1H4b), 6.80–6.83 (m, 1H,
NArH), 7.15–7.19 (m, 4H, NArH), 7.22 (d, 1H, C3ArH),
7.37–7.38 (d, 3H, C3ArH), 7.05 (s, 1H, C5ArH), 7.23–7.28
(m, 1H, C5ArH), 7.63–7.65 (d, 1H, C5ArH), 7.68–7.70 (t,
2H, C5ArH), 7.98 (s, 1H, NH).
13C NMR (100 MHz CDCl3,
ppm): 41.9, 57.9, 111.5, 113.7, 116.8, 118.9, 119.2, 119.9,
121.8, 112,5, 125.0, 127.0, 128.8, 128.9, 131.5, 134.1, 136.8,
145.1, 146.4. MS: m/z 371.1 (M+), 372.1(M+1). Anal. Calcd.
for C23H18ClN3: C, 74.29; H, 4.88; N, 11.30. Found: C, 74.31;
H, 4.86; N, 11.27%.2.2.4. 5-(1H-Indol-3-yl)-3-(4-nitrophenyl)-4,5-
dihydropyrazoline (2d)
Yield: 74.65%; reaction time: 16 min; m.p.:138–141 C; IR
(KBr): cm1 3361 (N–H), 1598 (C‚C), 1556(C‚N); 1H
NMR (400 MHz CDCl3, ppm) 5.91–5.94 (dd, 1H5c), 3.28–
3.32 (dd, 1H4a), 3.91–3.99 (dd, 1H4b), 6.70 (s, 1H, NArH),
6.86–6.91 (m, 1H, NArH), 7.02–7.04 (m, 3H, NArH), 7.1 (s,
1H, C3ArH), 7.04–7.05 (m, 3H, C3ArH), 7.41 (s, 1H,
C5ArH), 7.23–7.33 (m, 2H, C5ArH), 7.98–8.1 (t, 2H,
C5ArH), 8.23 (s, 1H, NH).
13C NMR (100 MHz CDCl3,
ppm): 41.0, 58.04, 112.4, 114.2, 115.2, 118.7, 119.4, 119.9,
121.8, 124.4, 124.5, 124.8, 126.5, 129.2, 137.3, 159.5, 144.0,
145.6, 146.8 MS: m/z 382.1 (M+), Anal. Calcd. for
C23H18N4O2: C, 72.24; H, 4.74; N, 14.65. Found: C, 72.27;
H, 4.72; N, 14.64%.2.2.5. 5-(1H-Indol-3-yl)-3-(4-methoxyphenyl)-4,5-
dihydropyrazoline (2e)
Yield: 67.36%, reaction time: 16 min; m.p.: 154–156 C; IR
(KBr): cm1 3284 (N–H), 1604 (C‚C), 1562 (C‚N); 1H
NMR (400 MHz CDCl3, ppm) 3.39 (s, 3H, OCH3), 5.99–
6.04(dd, 1H5c), 3.53–3.61 (dd, 1H4a), 3.68–3.75 (dd, 1H4b),
6.8–6.82 (m, 1H, NArH), 7.09–7.21 (m, 4H, NArH), 7.24–
7.28 (m, 4H, C3ArH), 7.31–7.35 (d, 1H, C5ArH), 7.48–7.5 (t,
1H, C5ArH), 7.65–7.69 (m, 1H, C5ArH), 7.06 (s, 1H,
C5ArH), 7.68–7.70 (m, 1H, C5ArH), 8.15 (s, 1H, NH).
13C
NMR (100 MHz CDCl3, ppm): 41.5, 55.7, 58.6, 111.2, 113.8,
114.7, 116.6, 118.2, 119.3, 120.3, 122.4, 126.9, 127.4, 129.7,
130.3, 137.1, 144.2, 145.9, 151.2. MS: m/z 367.1 (M+), Anal.
Calcd. for C24H21N3O: C, 78.45; H, 5.76; N, 11.44. Found:
C, 78.46; H, 5.74; N, 11.47%.
2.2.6. 5-(1H-Indol-3-yl)-3-(2-pyridyl)-4,5-dihydropyrazoline
(2f)
Yield: 71.26%, reaction time: 18 min; m.p.: 160–161 C; IR
(KBr): cm1 3400 (N–H), 1597(C‚C), 1552 (C‚N); 1H
NMR (400 MHz, DMSO, ppm) 6.06–6.71 (dd, 1H5c), 3.62–
3.73 (dd, 1H4a), 3.79–3.92 (dd, 1H4b), 6.82–6.83 (dd, 1H,
NArH), 7.17–7.22 (m, 4H, NArH), 7.73–7.74 (dd, 1H,
C3ArH), 7.8–7.86 (m, 2H, C3ArH), 8.67 (m, 1H, C3ArH),
7.1–7.12 (m, 2H, C5ArH), 7.24 (m, 1H, C5ArH), 7.33 (dd,
1H, C5ArH), 7.61–7.62 (m, 1H, C5ArH), 11.08 (s, 1H, NH).
13C NMR (100 MHz DMSO, ppm): 40.5, 55.2, 153.2, 143.1,
147.5, 112.8, 128.6, 117.4, 129.3, 126.1, 136.6, 123.5, 151.3,
151.9, 119, 116, 121.8, 127.3, 113, 136.1, 119.2, 111.6, 122,
120.3. MS: m/z 338.2 (M+), Anal. Calcd. for C22H18N4: C,
78.08; H, 5.36; N, 16.56. Found: C, 78.07; H, 5.38; N, 16.55%.
2.2.7. 5-(1H-Indol-3-yl)-3-(2-naphthyl)-4,5-dihydroisoxazoline
(2g)
Yield: 79.43%, reaction time: 16 min; m.p.: 203–204 C; IR
(KBr): cm1 3211 (N–H), 1606 (C‚C), 1578 (C‚N); 1H
NMR (400 MHz CDCl3, ppm) 6.03–6.13 (dd, 1H5c), 3.51–
3.77 (dd, 1H4a), 3.69–3.84 (dd, 1H4b), 6.81–6.83 (m, 1H,
NArH), 7.13–7.17 (m, 4H, NArH), 8.51–8.53 (m, 2H,
C3ArH), 7.84–7.87 (dd, 1H, C3ArH), 7.89–7.91 (m, 2H,
C3ArH), 7.51–7.53 (m, 2H, C3ArH), 7.05 (s, 1H, C5ArH),
7.21–7.26 (m, 1H, C5ArH), 7.62–7.67 (d, 1H, C5ArH), 7.69–
7.71 (m, 2H, C5ArH), 8.15 (s, 1H, NH).
13C NMR
(100 MHz CDCl3, ppm): 41, 57.2, 151.2, 143.6, 113.2, 126.6,
116.8, 128.4, 127.1, 126.7, 133.4, 136, 128.2, 126, 116.3,
127.1, 136.6, 118.9, 111.2, 122.3, 120.2. MS: m/z 387.1 (M+).
Anal. Calcd. for C27H21N3: C, 83.69; H, 5.47; N, 10.84.
Found: C, 83.68; H, 5.45; N, 10.87%.
2.2.8. 5-(5-bromo-1H-Indol-3-yl)-3-(phenyl)-4,5-
dihydropyrazoline (2h)
Yield: 72.85%, reaction time: 18 min; m.p.: 197–198 C; IR
(KBr): cm1 3418 (N–H), 1606 (C‚C), 1583 (C‚N); 1H
NMR (400 MHz CDCl3, ppm) 5.81–5.88 (dd, 1H5c), 3.34–
3.39 (dd, 1H4a), 3.88–3.96 (dd, 1H4b), 6.91 (s, 1H, NArH),
6.85–6.9 (m, 1H, NArH), 7.01–7.05 (m, 3H, NArH), 7.13 (s,
1H, C3ArH), 7.66–7.69 (m, 4H, C3ArH), 7.21–7.3 (dd, 2H,
C5ArH), 7.32–7.38 (t, 2H, C5ArH), 7.13–7.86, 7.99 (s, 1H,
NH). 13C NMR (100 MHz CDCl3, ppm): 41.8, 57.2, 111.4,
113.6, 116.8, 118.1, 119.3, 120.0, 121.9, 124.9, 127.0, 128.7,
Synthesis, characterization and screening for antidepressant and anticonvulsant activity of 4,5-dihydropyrazole bearing 591131.6, 134.3, 136.9, 145.2, 146.6. MS: m/z 417.1 (M+). Anal.
Calcd. for C23H18BrN3: C, 66.36; H, 4.36; N, 10.09. Found:
C, 66.38; H, 4.37; N, 10.11%.
2.2.9. 5-(5-methoxy-1H-Indol-3-yl)-3-(phenyl)-4,5-
dihydropyrazoline (2i)
Yield: 77.74%, reaction time: 17 min; m.p.: 187–188 C; IR
(KBr): cm1 3245 (N–H), 1600 (C‚C), 1610 (C‚N); 1H
NMR (400 MHz CDCl3, ppm) 3.71 (s, 3H, OCH3), 5.82–
6.01 (dd, 1H5c), 3.52–3.66 (dd, 1H4a), 3.69–3.83 (dd, 1H4b),
6.81–6.83 (m, 1H, NArH), 7.13–7.17 (m, 4H, NArH), 7.09–
7.1 (t, 1H, C3ArH), 7.32–7.36 (m, 2H, C3ArH), 7.61–7.68
(m, 2H, C3ArH), 6.72 (dd, 1H, C5ArH), 7.05 (d, 1H,
C5ArH) 7.23–7.25 (m, 2H, C5ArH), 8.10 (s, 1H, NH).
13C
NMR (100 MHz CDCl3, ppm): 41.23, 55.8, 57.12, 111.6,
113.1, 116.5, 119.0, 119.6, 119.8, 121.7, 124.5, 126.8, 128.5,
131.6, 134.4, 136.6, 145.6, 146.5, 155.0. MS: m/z 368.23
(M+), Anal. Calcd. for C24H21N3O: C, 78.45; H, 5.76; N,
11.44. Found: C, 78.49; H, 5.75; N, 11.42%.
2.2.10. 5-(1H-Indol-3-yl)-3-(2-pyrolyl)-4,5-dihydropyrazoline
(2j)
Yield: 70.36%, reaction time: 18 min; m.p.:201–202 C; IR
(KBr): cm1 3212 (N–H), 1603 (C‚C), 1596(C‚N); 1H
NMR (400 MHz CDCl3, ppm) 13.03 (s, 1H, NHpyr), 5.99–
6.12 (dd, 1H5c), 3.49–3.67 (dd, 1H4a), 3.68–3.81 (dd, 1H4b),
6.8–6.82 (d, 1H, NArH), 7.13–7.26 (m, 4H, NArH), 6.13–
6.15 (t, 1H, C3ArHpyr), 6.5–6.53 (dd, 1H, C3ArHpyr), 6.91–
6.94 (m, 1H, C3ArHpyr), 7.65–7.69 (m, 2H, C5ArH), 7.06 (s,
1H, C5ArH), 7.88–7.91 (m, 2H, C5ArH), 8.10 (s, 1H, NHind).
13C NMR: 41.2, 57, 154.2, 143, 114.1, 129.3, 117.2, 117.9,
111.6, 110.1, 118.3, 116.1, 122.5, 127.1, 136.2, 119.3, 111,
122.5, 120.2. MS: m/z 327.2 (M+), Anal. Calcd. for
C21H18N4: C, 77.28; H, 5.56; N, 17.17. Found: C, 77.30; H,
5.57; N, 17.13%.
2.2.11. 5-(1H-Indol-3-yl)-3-(2-thienyl)-4,5-dihydropyrazoline
(2k)
Yield: 68.82%, reaction time: 18 min; m.p.:192–194 C; IR
(KBr): cm1 3243 (N–H), 1592(C‚C), 1576 (C‚N); 1H
NMR (400 MHz CDCl3, ppm) 6.06–6.12 (dd, 1H5c), 3.51–
3.61 (dd, 1H4a), 3.69–3.78 (dd, 1H4b), 6.81–6.83 (d, 1H,
NArH), 7.14–7.24 (m, 4H, NArH), 7.43–7.49 (m, 2H,
C3ArHthienyl), 7.55–7.57 (dd, 1H, C3ArHthienyl), 7.61–7.67 (m,
2H, C5ArH), 7.71–7.79 (m, 3H, C5ArH), 8.14 (s, 1H, NH).
13C NMR (100 MHz CDCl3, ppm): 41.5, 57.2, 154.6, 143.3,
113.1, 129, 117.1, 143, 126.4, 127, 127.1, 125.3, 116.3, 122.4,
127.3, 136.1, 119.1, 111.4, 122.2, 120.4. MS: m/z 344.1 (M+),
Anal. Calcd. for C21H17N3S: C, 73.44; H, 4.99; N, 12.23.
Found: C, 73.47; H, 4.97; N, 12.24%.
2.2.12. 5-(1H-Indol-3-yl)-3-(4-hydroxyphenyl)-4,5-
dihydropyrazoline (2l)
Yield: 77.13%, reaction time: 16 min; m.p.:173–174 C; IR
(KBr): cm1 3316 (N–H), 3408 (OH), 1602 (C‚C), 1558
(C‚N); 1H NMR (400 MHz CDCl3, ppm) 11.81 (s, 1H,
OH), 6.12–6.19 (dd, 1H5c), 3.56–3.63 (dd, 1H4a), 3.71–3.85
(dd, 1H4b), 6.63 (s, 1H, NArH), 6.85–6.89 (m, 1H, NArH),
7.03–7.05 (m, 3H, NArH), 7.21 (d, 1H, C3ArH), 7.07–7.11
(m, 3H, C3ArH), 7.26–7.38 (m, 3H, C5ArH), 7.96–8.0 (m,2H, C5ArH), 8.15 (s, 1H, NH).
13C NMR: 41.3, 57.5, 154.6,
143.2, 113.9, 129.2, 117, 126.3, 130.7, 116, 159.7, 116.3,
127.6, 136.6, 119.4, 111.3, 122.1, 120.1. MS: m/z 354.5 (M+),
Anal. Calcd. for C23H19N3O: C, 78.16; H, 5.42; N, 11.89.
Found: C, 78.17; H, 5.41; N, 11.91%.
2.2.13. 5-(1H-Indol-3-yl)-3-(4-bromophenyl)-4,5-
dihydropyrazoline (2m)
Yield: 75.39%, reaction time: 17 min; m.p.:179–181 C; IR
(KBr): cm1 3329 (N–H), 1602 (C‚C), 1586 (C‚N); 1H
NMR (400 MHz CDCl3, ppm) 5.61–5.65 (dd, 1H5c), 3.26–
3.31 (dd, 1H4a), 3.79–3.85 (dd, 1H4b), 6.8 (s, 1H, NArH),
6.82–6.9 (m, 1H, NArH), 7.01–7.04 (m, 3H, NArH), 7.13 (s,
1H, C3ArH), 7.03–7.05 (m, 3H, C3ArH),7.4 (s, 1H, C5ArH),
7.21–7.3 (m, 2H, C5ArH), 7.67–7.7 (m, 2H, C5ArH), 6.80–
7.70, 7.99 (s, 1H, NH). 13C NMR (100 MHz CDCl3, ppm):
41.5, 57.6, 111.2, 113.1, 116.3, 117.4, 120.4, 120.8, 121.3,
122.2, 125.7, 129.3, 129.8, 131.3, 131.9, 133.4, 135.8, 143.6,
147.4. MS: m/z 416.31 (M+), Anal. Calcd. for C23H18BrN3:
C, 66.36; H, 4.36; N, 10.09. Found: C, 66.39; H, 4.35; N,
10.11%.
2.3. Antidepressant activity
The synthesized compounds were screened for their antide-
pressant activity using the forced swimming test (FST) (Porsolt
et al., 1977). Adult male albino Swiss-Webster (20 ± 2 g) mice
were used with free access to food and water. They were
housed in a group of six. The approval of the Institutional
Animal Ethics Committee (IAEC) of R. C. Patel Institute of
Pharmaceutical education and Research Shirpur (Maharash-
tra, India) was taken prior to the start of the experiments.
On the test day, mice were dropped one at a time into glass
cylindrical container (diameter 10 cm, height 25 cm), contain-
ing approximately 20 cm of water at 25±1 C temperature.
Water was replaced between every trial. On this day, mice were
assigned into different groups (n= 6–9 for each group). The
synthesized compounds (100 mg/kg), Imipramine (20 mg/kg),
and Fluoxetine (20 mg/kg) suspended in aqueous Tween 80
(0.5%) were injected as intraperitoneally (ip) [n= 6]. Control
animals received 0.5% aqueous solution of Tween 80. Then,
after 1/2 h the mice were dropped individually into the glass
cylinder and left in the water for 6 min. After the ﬁrst 2 min
of the initial vigorous struggling, the animals were immobile.
A mouse was judged immobile if it ﬂoated in the water in an
upright position and made only slight movements in order to
prevent sinking. The duration of immobility was recorded dur-
ing the last 4 min of the 6-min test. Statistical analysis was per-
formed by one-way ANOVA followed by Dunnett’s test to
evaluate the results. The results of FST are summarized in
Fig. 1.
2.4. Anticonvulsant activity
The title compounds were tested for anticonvulsant activity
against the PTZ induced convulsions in mice according to
the reported method (Turner, 1965; Krall et al., 1978). All
the solutions of standard drugs and PTZ were prepared in
0.9% sodium chloride solution. The test compounds were
administered in the form of suspension made up of 0.5%
Tween 80 in 0.9% sodium chloride solutions. All of the test
Figure 1 The effect of treatment with 2a–m (100 mg/kg, i.p.), imipramine (20 mg/kg, i.p.) and ﬂuoxetine (20 mg/kg, i.p.) on the
immobility time in FST (Data were analysed by one way ANOVA followed by Dunnet’s test. n= 6. Values are represented as
mean ± S.E.M. compared with control group. P< 0.05 was considered statistically signiﬁcant, ***P < 0.001, ns = not signiﬁcant. #
indicates compounds 2b, 2e and 2k were employed at the dose of 20 mg/kg.
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in a volume of 0.01 ml/g for mice at doses. Pentylenetetrazole
(80 mg/kg) dissolved in 0.9% sodium chloride solution was
administered in the posterior midline of the mice and the onset
and severity of convulsions were noted for the control group.
The test group was administered with the selected compounds
0.5 h prior to the administration of PTZ. The absence or pres-
ence of an episode of clonic convulsions was taken as the end
point. The data were analysed by one-way ANOVA followed
by Dunnett’s test using Graph Pad Prism software. All the val-
ues were expressed as mean ± SEM. Comparison of anticon-
vulsant activity by the PTZ induced seizure method
(compared with standard) for compounds 2a–m are shown in
Table 2.
2.5. Neurotoxicity screening
Rotarod test has been performed to detect the minimal motor
deﬁcit in mice (Vogel, 2002). The animal was placed on a
3.2 cm diameter knurled rod rotating at 6 rpm. Normal mice
can remain on a rod rotating at this speed indeﬁnitely. Neuro-
logical toxicity is deﬁned as the failure of the animal to remain
on the rod for 1 min (Table 2).
3. Results and discussion
3.1. Chemistry
The synthesis of the titled compounds (2a–m) has been carried
out as being depicted in (Scheme 1). The starting compound 3
formyl indole (Organic Syntheses, 1963) and substituted indo-
lyl chalcones 1a–m (Panda and Chaudhari, 2008) were pre-
pared according to the known procedures. Finally, the
mixture of substituted chalcones 1a–m and phenyl hydrazinehydrochloride was irradiated under microwave without solvent
to afford corresponding indolyl pyrazoline derivatives 2a–m.
All the synthesized compounds were characterized by their
physical (Table 1), and spectral data.
The IR spectra of the pyrazoline derivatives 2a–m exhibited
C‚N stretching vibration in the region of 1626–1516 cm1.
Disappearance of the carbonyl (C‚O) peak at around 1710–
1650 cm1 revealed the formation of indolyl pyrazolines. In
the 1H NMR spectrum, C4 (H4a, H4b) and C5 (H5c) protons
of the pyrazoline ring exhibited doublets of doublets at 3.29–
3.39 (d ppm, H4a), 3.80–3.87 (d ppm, H4b) and 5.60–5.69 (d
ppm, H5c), respectively, conﬁrms the formation of the pyrazo-
line ring.
3.2. Antidepressant activity
The forced swimming test is a behavioral test used to predict the
efﬁcacy of antidepressant treatments (Porsolt et al., 1977). It has
good predictive value for antidepressant potency in humans
because of its sensitivity and selectivity (Willner and Mitchell,
2002). As depicted in Fig. 1, all of the compounds except 2d
signiﬁcantly reduced the immobility times at a dose of 100 mg/
kg compared with a control (P< 0.001). The immobility time
of the mice treated with 2d did not statistically differ from
the control value (control, 93.17 ± 3.94 s; 2d, 80.67 ± 7.43 s
(P< 0.05). An analysis of the antidepressant activities of com-
pounds 2a–m (Fig. 1) showed the subsequent structure–activity
relationships. Amongst the indolyl pyrazolines derivatives, the
substituent group on the benzene ring appeared to greatly inﬂu-
ence the FST activity. The presence of electron releasing groups
(OCH3, CH3 and OH) on the phenyl ring of indolyl pyrazolines
showedpromising antidepressant activity.Whereas substitution
of the methoxy group at the 5th position of the indole ring
retains the antidepressant activity. Amongst the compounds,
Table 1 Physical data of 5-(substituted-1H-Indol-3-yl)-3-(substitutedaryl)-4, 5-dihydropyrazoline derivatives 2a–m synthesized via
Scheme 1.
Compound Ar R Yield (%)a m.p. (C)
2a H 85.46 178–180
2b
CH3
H 84.52 175–177
2c
Cl
H 88.26 160–161
2d
N+
O-
O H 74.65 138–141
2e
OCH3
H 67.36 154–156
2f N H 71.26 160–161
2g H 79.43 203–204
2h Br 72.85 197–198
2i OCH3 77.94 187–188
2j
N
H
H 70.36 201–202
2k
S
H 68.82 192–194
2l
OH
H 77.13 173–174
2m
Br
H 75.39 179–181
a All yields refer to products puriﬁed by column chromatography (Chloroform:Acetone 16:1).
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O
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CHO
R
N
H
O
Ar
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Scheme 1 Synthesis of 3-(1,3-diphenyl-4,5-dihydro-1H-pyrazol-5-yl)-1H-indole derivatives (2a-m) under microwave.
Table 2 Anticonvulsant activity of compounds 2a–m in PTZ induced convulsions.
Treatment Onset time clonic convulsion
durationb ± SEM (s)
Neurotoxicity
Vehicle + PTZ 60.33 ± 1.62 ND
Diazepam+ PTZ 128.8 ± 2.33 –
2a+ PTZ 74.0 ± 2.33 –
2b+ PTZ 61.67 ± 1.70ns ND
2c+ PTZ 116.3 ± 1.54 –
2d+ PTZ 109.8 ± 2.86 –
2e+ PTZ 65.6 ± 3.46ns ND
2f+ PTZ 93.5 ± 3.27 –
2g+ PTZ 80.6 ± 4.59*** ND
2h+ PTZ 99.0 ± 2.76 –
2i+ PTZ 74.3 ± 3.42 –
2j+ PTZ 96.5 ± 3.39 ND
2k+ PTZ 90.6 ± 2.14 ND
2l+ PTZ 82.6 ± 3.62 ND
2m+ PTZ 103.3 ± 4.24 –
2c+ PTZa 111.7 ± 2.4 –
2d+ PTZa 102.8 ± 3.45 –
2m+ PTZa 97.8 ± 3.54 –
Compounds 2a–m were administered at a dose of 100 mg/kg.
ND indicates not done; A dash (–) indicates non neurotoxic.
a Equimolar dose to standard drug (Diazepam).
b Each score represents the mean ± SEM of six mice, signiﬁcantly different from the control score at P< 0.0001, ***(P< 0.001) indicates the
level of statistical signiﬁcance, ns = not signiﬁcant.
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(2e), 5-(1H-Indol-3-yl)-3-(4-methylphenyl)-4,5-dihydropyrazo-
line (2b) and 5-(1H-Indol-3-yl)-3-(2-thienyl)-4,5-dihydropyraz-
oline (2k) were found to be the most active antidepressant
compounds and signiﬁcantly reduced the duration of immobil-
ity times at 100 mg/kg dose level when compared to the control
(P< 0.001). Moreover active compounds, 2b, 2e and 2k at the
dose of 20 mg/kg i.p also exhibited signiﬁcant antidepressant
activity compared with imipramine and ﬂuoxetine
(P< 0.001). Comparing derivatives with different halogen
substituents on the benzene ring, their activity order wasCl > Br > NO2 and it resulted in a decrease in antidepressant
effect of existing pyrazoline derivatives. Atom bromine on the
phenyl ring gave the same contribution to the antidepressant
activity compared to Br atom at the 5th position of indole
of the target compounds. Replacement of phenyl ring by
heterocyclic nucleus on the proposed scaffold increases
antidepressant activity and their activity order was thienyl >
pyrrole > pyridine. Derivatives with an electron donating
group on the phenyl ring of indolyl pyrazoline appear to be
a more promising structural feature than with an electron
withdrawing group for antidepressant like effects.
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The synthesized compounds 2a–m were also evaluated for anti-
convulsant activity against PTZ induced seizures in mice and
the results from these experiments are shown in Table 2.
Compounds 2c and 2d exhibited the most protective class of
the tested compounds and other compounds 2f, 2j, 2h, 2k and
2m exhibited a moderate protection against clonic seizures in-
duced by injection of scPTZ. While evaluating the anticonvul-
sant activity, it was observed that compounds carrying an
electron withdrawing group (2c, 2d and 2m) on the phenyl ring
C3 of pyrazoline had shown profound activity in comparison
to compounds having electron releasing group (2b, 2e and
2l). Some selected compounds have been further tested for
their neurotoxicity using the rotarod toxicity test. None of
the synthesized compounds showed neurotoxicity as shown
in Table 2.
4. Conclusion
In summary, we have reported a simple, eco-friendly, high
yielding microwave assisted method for the synthesis of indolyl
pyrazoline derivatives, as a novel candidate for antidepressant
as well as anticonvulsant. Compounds 2b, 2e and 2k induced
amazing antidepressant activity compared to standard drugs
at the dose of 20 mg/kg. Other compounds 2f, 2i and 2j fur-
nished good antidepressant activity. Generally, derivatives
with an electron donating group on the phenyl ring of indolyl
pyrazoline possess remarkable antidepressant activity. More-
over, compounds 2c and 2d revealed the most protective class
of the tested compounds against clonic seizures induced by
scPTZ. It is worth aphorism that the compounds having elec-
tron withdrawing substituent at the phenyl ring of indolyl pyr-
azoline exhibited a remarkable anticonvulsant activity.
Consequently, such compounds would signify a fruitful matrix
for the development of a new class of anticonvulsant and anti-
depressant agent and would warrant further investigation and
derivatization as a promising scaffold.
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